17,261 trials
Transfusion-dependent Thalassemia · Non-transfusion-dependent Thalassemia
Primary: Number of Participants Preferring Deferasirox FCT or DT at Week 48 Based on Preference Questionnaire (Item 2) — 10; 121; 3 Participants — p=<.0001
Malignant Pleural Mesothelioma · Non-Small Cell Lung Cancer
Primary: Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) — 4; 0; 0; 1 Participants
Unresectable Adenocarcinoma of the Esophagus · Metastatic Adenocarcinoma of the Esophagus · Unresectable Adenocarcinoma of Gastric Cardia
Primary: Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the…
Patients Undergoing Photodynamic Therapy Using Porfimer Sodium
Primary: The First Day on Which Patients Are Free From Symptoms of Phototoxicity Following Phototesting
Chronic Kidney Disease · End Stage Renal Disease · Anemia
Primary: Change From Baseline in Hb Over Time — 10.05; 1.26; 1.58; 1.94 g/dL
Dialysis · Anemia
Primary: Maximum Change From Baseline in Hb During Weeks 3-13 — 8.1; 8.5; 8.4; 8.7 grams/deciliter (g/dL) — p=0.0757
Non-Hodgkins Lymphoma · Multiple Myeloma · B-All
Primary: Best Response and Overall Response Rate — 33.3; 0; 16.7; 18.2 percentage of participants
Bacterial Infection
Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Primary: Overall Response Rate — 13.5 percentage of participants
Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Complete Response (CR) — 12 Participants
Advanced Pancreatic Cancer
Primary: Safety and Tolerability. — 73; 35; 4; 0 participants
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Menopause · Hot Flashes
Primary: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 — -4.2; -6.1; -7.2; -7.0 VMS per…
Melanoma · Non-small Sell Lung Cancer (NSCLC) · Triple Negative Breast Cancer
Primary: Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days) — 270; 1150; 3110; 575 day*ug/mL
Wilson Disease
Primary: Percentage Of Participants With Normalized Concentrations Of NCC — 85.7 percentage of participants